<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715182</url>
  </required_header>
  <id_info>
    <org_study_id>CTKI258A2107</org_study_id>
    <secondary_id>2007-004391-39</secondary_id>
    <nct_id>NCT00715182</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer</brief_title>
  <official_title>A Phase I/II Multi-center, Open Label Study of TKI258 Administered Orally on an Intermittent Schedule in Adult Patients With Advanced or Metastatic Renal Cell Cancer (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics
      (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of
      subjects who have been diagnosed with advanced or metastatic renal cell cancer that is
      refractory to standard therapy or for which no curative standard therapy exists.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: To determine the MTD of TKI258, administered orally on a 5 days on/2 days off schedule to adult patients with advanced or metastatic RCC whose diseases have progressed despite standard therapy or for whom no standard anticancer therapy exists.</measure>
    <time_frame>at end of phase I</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: To determine anti-tumor activity of TKI258 in advanced or metastatic RCC patients with predominant clear cell histology that have been previously treated with VEGF receptor tyrosine kinase inhibitor (sunitinib and/or sorafenib).</measure>
    <time_frame>at end of phase II</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety profile of TKI258</measure>
    <time_frame>cycle 1: day 1,8,15,26; cycle 2: day 15, 28; cycle 3+: day 28 &amp; at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effect of TKI258 on plasma biomarkers, pre- and post-treatment</measure>
    <time_frame>cycle 1: day 1,15,26; cycle 2: 15 &amp; 28; every other cycles: day 28 &amp; at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the pharmacokinetic and pharmacodynamic relationship</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the single and multiple-dose PK profiles of oral TKI258</measure>
    <time_frame>cycle 1: day 1, 8, 15 &amp;26; cycle 2 &amp; 3: day 15 &amp; 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival and over all survival</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Advanced/ Metastatic Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>TKI258</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TKI258</intervention_name>
    <arm_group_label>TKI258</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For phase I, confirmed advanced/ metastatic renal cell carcinoma for which no other
             therapeutic options exist.

          -  For phase II, must have been previously treated with VEGF receptor tyrosine kinase
             inhibitor (sunitinib and/or sorafenib).

          -  For phase II, must have at least one measurable lesion at baseline.

          -  For both phase I &amp; II, measurable histologically or cytology confirmed progressive
             metastatic renal cell carcinoma with predominant clear cell histology (&gt;50%).

          -  At least 4 weeks must have elapsed since any prior anti-cancer therapy (6 weeks for
             nitrosoureas or mitomycin C).

          -  Must have recovered from adverse events (to grade 1 or less toxicity according to
             CTCAE 3.0) due to agents administered more than 28 days earlier.

          -  Must be eighteen years of age or older

          -  ECOG performance status 0 or 1.

          -  Must meet baseline laboratory requirement

          -  Life expectancy greater than or equal to 12 weeks.

          -  Signed and witnessed informed consent prior to any screening procedures.

        Exclusion Criteria:

          -  Concurrent therapy with any other investigational agent within 28 days prior to
             baseline.

          -  Pregnant or breast feeding women.

          -  Clinically significant cardiac disease (New York Heart Association, Class III or IV)
             or impaired cardiac function or clinically significant cardiac diseases.

          -  Uncontrolled infection.

          -  Diabetes mellitus with signs of clinically significant peripheral vascular disease.

          -  Previous pericarditis; clinically significant pleural effusion in the previous 12
             months or current ascites requiring two or more interventions/month.

          -  Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis,
             adrenal or thyroid glands.

          -  Prior acute or chronic pancreatitis of any etiology.

          -  Acute and chronic liver disease and all chronic liver impairment.

          -  Malabsorption syndrome or uncontrolled gastrointestinal symptoms (such as nausea,
             diarrhea and vomiting) with toxicity greater than NCI CTCAE grade 2.

          -  Other severe, acutem or chronic medical or psychiatric condition or laboratory
             abnormality that may interfere with the interpretation of study results and, in the
             judgement of the investigator, would make the subject inappropriate for this study.

          -  Treatment with any of the medications that have a potential risk of prolonging the QT
             interval or inducing Torsades de Points and the treatment cannot be discontinued or
             switched to a different medication prior to starting study drug.

          -  Use of ketoconazole, erythromycin, carbamazapine, phenobarbital, rifampin, phenytoin
             and quinidine 2 weeks prior to baseline.

          -  Major surgery within 28 days prior to starting study drug or who have not recovered
             from side effects of such therapy.

          -  Known diagnosis of HIV infection (HIV testing is not mandatory).

          -  History of another clinically significant primary malignancy that requires active
             intervention.

          -  Patients with brain metastases as assessed by radiologic imaging.

          -  Alcohol or substance abuse disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, ROC</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Cell Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

